Navigation Links
ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries
Date:11/21/2009

WASHINGTON, Nov. 21 /PRNewswire/ -- An urgent need for new medicines to treat neglected infectious diseases in the developing world has prompted a growing number of collaborations among academic researchers, non-profit product development partnerships (PDPs), and pharmaceutical and biotechnology companies. As noted today in a symposium at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), these collaborations are opening up new avenues of access to industry technology, expertise, and capabilities, enabling the harnessing of industry resources for new product innovation.

The need for these collaborations between industry and global health non-profits results from the lack of effective prevention or treatments for many infectious diseases of the developing world. There is a tremendous need for new R&D that could lead to new cures. Despite substantial progress in improving delivery of existing medicines for infectious diseases in the developing world, there are still major gaps in disease prevention, diagnosis, and treatment that must be alleviated through development of new medicines.

"Industry/public sector product development collaborations are one of the success stories for the developing world, as biopharmaceutical companies are discovering that investment in global health R&D is consistent with their broader commercial strategies," observed Dr. Christopher D. Earl, former chief executive officer of BIO Ventures for Global Health, who organized the symposium. "The participants in this symposium highlight how their organizations have made substantial progress in moving unused compounds from companies' shelves to the laboratory and ultimately to the clinic. By allowing experts access to assets that industry has amassed, these collaborations have spurred the development of new medicines for malaria, tuberculosis, and various parasite-borne diseases."

The symposium, "Rummaging Through Pharma's Attic: Taking Advantage of Industry's Unused Assets to Generate New Products for Infectious Diseases of the Developing World," featured presentations on the following topics:

  • Finding a Diamond in the Rough: Screening Industry's Libraries Against Tropical Parasites -- James H. McKerrow, University of California, San Francisco
  • Raiding the Deep Freeze: The Fexinidazole Story - Robert Don, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland
  • Will They Respect You in the Morning: Forging Partnerships with Biotech and Big Pharma -- Jorg J. Mohrle, Medicines for Malaria Venture, Geneva, Switzerland
  • Extending a Hand: Eli Lilly's TB Drug Discovery Partnership -- Gail H. Cassell, Eli Lilly & Co., Indianapolis, IN

The aim of the symposium was to illustrate how industry/public sector collaborations help to bridge what Dr. Earl calls an "innovation gap" for new treatments for infectious diseases of poverty. "Historically, most global health products lacked a profitable market that would justify investing the millions of dollars needed to develop new medicines," he explained. "Additionally, most biotechnology companies lacked experience with the pathogens that afflict poor populations, and were largely unfamiliar with medical practice and pharmaceutical distribution in the developing world. Those barriers, combined with the perceived lack of incentives and management time to devote to non-core activities, conspired to stifle industry investment in global medicines."

"That is all changing, as donors such as the Bill & Melinda Gates Foundation and the Wellcome Trust, federal agencies such the National Institutes of Health and industry itself are supporting product development collaborations," Dr. Earl continued. "Disease experts are increasingly gaining access to companies' compound libraries, technology platforms, and shelved products, and the result is greater access to effective medicines among the populations that need them."

"The story of these product development collaborations is one of pioneering companies and public sector partners creating successful models to the benefit of global health," said Thomas Wellems, MD, PhD, president of ASTMH. "As the ASTMH is committed to improved global health, we look forward to and actively encourage continued collaborations in this area."

About the ASTMH

The American Society of Tropical Medicine and Hygiene (ASTMH), founded in 1903, is a worldwide organization of scientists, clinicians and program professionals whose mission is to promote global health through the prevention and control of infectious and other diseases that disproportionately afflict the global poor.

SOURCE The American Society of Tropical Medicine and Hygiene


'/>"/>
SOURCE The American Society of Tropical Medicine and Hygiene
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
4. DaVita Abstracts Accepted Into National Kidney Foundations 2009 Spring Symposium
5. Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th
6. Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
7. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
8. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
9. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
10. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
11. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, Case ... successful education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning ...
(Date:1/19/2017)... ... ... here, many people will have to clear snow with snow blowers or shovels from driveways ... can be dangerous when used incorrectly. That’s why Amica Insurance is sharing the ... blowers:, , When removing wet snow or debris from the blower, ...
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic ... video series that uses humor to highlight ways to improve heart health and overall ... Good™ movement, which is designed to inspire all Americans to make small changes that ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus ... condensed version of the clinic’s leading recovery program. , “We know it’s ...
(Date:1/19/2017)... IL (PRWEB) , ... January 19, 2017 , ... ... N.A., announced it recently provided a new $11,250,000 senior credit facility to Sunrise, ... new MB credit facility were used to facilitate a recapitalization of MedPro led ...
Breaking Medicine News(10 mins):